Studies have demonstrated the effectiveness of targeting CSPG4 with monoclonal antibody (mAb)-based immunotherapy, both in vitro and in mouse models, to treat melanoma, triple-negative breast cancer, and mesothelioma [19,21,30]. This evidence concerns the gene CSPG4 and mesothelioma.